Literature DB >> 19383883

Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study.

Jonathan L Hecht1, Joanne Kotsopoulos, Susan E Hankinson, Shelley S Tworoger.   

Abstract

Hormone receptor expression in tumors may offer etiologic information for ovarian cancer, particularly in light of known associations with hormonal and reproductive risk factors. Tissue microarrays constructed from 157 paraffin-embedded blocks of epithelial ovarian tumors collected from participants in the Nurses' Health Study were stained for estrogen receptor-alpha (ERalpha) and progesterone receptor (PR). We examined receptor expression by invasion, grade, and histologic subtype. Multivariate unconditional logistic regression was used to evaluate whether hormonal, reproductive, and anthropometric risk factors were differentially associated with the risk of developing receptor-positive or receptor-negative ovarian tumors compared with controls. PR-expressing tumors were less likely to be invasive (P = 0.05) and more likely to be of a lower grade (P < 0.001) and stage (P = 0.007) compared with PR- tumors. ERalpha status was not associated with any pathologic features of the tumor (P > 0.34). Increasing age, being postmenopausal, and postmenopausal hormone use were associated with an increased risk of developing ERalpha+, but not ERalpha- (P(heterogeneity) = 0.001, 0.06, and 0.06, respectively) and PR-, but not PR+, tumors (P(heterogeneity) = 0.08, 0.003, and 0.40, respectively), whereas height was only associated with the risk of developing PR- disease (P(heterogeneity) = 0.08). There were no clear risk differentials with OC use, parity, body mass index, or physical activity. Reproductive and hormonal risk factors are associated with subgroups of ovarian cancer defined by histologic subtype or ERalpha and PR status. These finding support specific models of hormone mediated triggers of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383883      PMCID: PMC2814542          DOI: 10.1158/1055-9965.EPI-08-1214

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  48 in total

1.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

Authors:  C Rodriguez; A V Patel; E E Calle; E J Jacob; M J Thun
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

Review 2.  Height, leg length, and cancer risk: a systematic review.

Authors:  D Gunnell; M Okasha; G D Smith; S E Oliver; J Sandhu; J M Holly
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

3.  Prospective study of recreational physical activity and ovarian cancer.

Authors:  E R Bertone; W C Willett; B A Rosner; D J Hunter; C S Fuchs; F E Speizer; G A Colditz; S E Hankinson
Journal:  J Natl Cancer Inst       Date:  2001-06-20       Impact factor: 13.506

4.  Steroid hormone receptors and long term survival in invasive ovarian cancer.

Authors:  K Münstedt; J Steen; A G Knauf; T Buch; R von Georgi; F E Franke
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

Review 5.  Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells.

Authors:  I H L Hamelers; P H Steenbergh
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

6.  Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.

Authors:  M Fujimura; T Hidaka; K Kataoka; Y Yamakawa; S Akada; A Teranishi; S Saito
Journal:  Am J Surg Pathol       Date:  2001-05       Impact factor: 6.394

7.  Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Margaret A Gates; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 8.  Estrogens and epithelial ovarian cancer.

Authors:  Séverine Cunat; Pascale Hoffmann; Pascal Pujol
Journal:  Gynecol Oncol       Date:  2004-07       Impact factor: 5.482

9.  Estrogen replacement therapy and ovarian cancer.

Authors:  Aaron R Folsom; Jeffrey P Anderson; Julie A Ross
Journal:  Epidemiology       Date:  2004-01       Impact factor: 4.822

10.  Methods to evaluate risks for composite end points and their individual components.

Authors:  Robert J Glynn; Bernard Rosner
Journal:  J Clin Epidemiol       Date:  2004-02       Impact factor: 6.437

View more
  14 in total

Review 1.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

2.  Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.

Authors:  Holly R Harris; Megan S Rice; Amy L Shafrir; Elizabeth M Poole; Mamta Gupta; Jonathan L Hecht; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-13       Impact factor: 4.254

3.  Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary.

Authors:  Hiroshi Kobayashi; Hiroshi Shigetomi; Chiharu Yoshimoto
Journal:  Oncol Lett       Date:  2015-05-26       Impact factor: 2.967

4.  Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.

Authors:  Monique A Spillman; Nicole G Manning; Wendy W Dye; Carol A Sartorius; Miriam D Post; Joshua Chuck Harrell; Britta M Jacobsen; Kathryn B Horwitz
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

5.  The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.

Authors:  Amy L Shafrir; Megan S Rice; Mamta Gupta; Kathryn L Terry; Bernard A Rosner; Rulla M Tamimi; Jonathan L Hecht; Shelley S Tworoger
Journal:  Gynecol Oncol       Date:  2016-10-05       Impact factor: 5.482

6.  Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium.

Authors:  Stefanie Aust; Anna Bachmayr-Heyda; Petra Pateisky; Dan Tong; Silvia Darb-Esfahani; Carsten Denkert; Radoslav Chekerov; Jalid Sehouli; Sven Mahner; Toon Van Gorp; Ignace Vergote; Paul Speiser; Reinhard Horvat; Robert Zeillinger; Dietmar Pils
Journal:  Mol Cancer       Date:  2012-09-14       Impact factor: 27.401

7.  A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil.

Authors:  Marcela F Paes; Renata D Daltoé; Klesia P Madeira; Lucas Cd Rezende; Gabriela M Sirtoli; Alice L Herlinger; Leticia S Souza; Luciana B Coitinho; Débora Silva; Murilo F Cerri; Ana Cristina N Chiaradia; Alex A Carvalho; Ian V Silva; Leticia Ba Rangel
Journal:  J Ovarian Res       Date:  2011-08-09       Impact factor: 4.234

8.  Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).

Authors:  Chiharu Uekuri; Hiroshi Shigetomi; Sumire Ono; Yoshikazu Sasaki; Miyuki Matsuura; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2013-08-28       Impact factor: 2.967

9.  Estrogen Receptor-β Expression of Ovarian Tumors and Its Association with Ovarian Cancer Risk Factors.

Authors:  Amy L Shafrir; Ana Babic; Margaret Gates Kuliszewski; Megan S Rice; Mary K Townsend; Jonathan L Hecht; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-20       Impact factor: 4.254

10.  MiR-26a promotes ovarian cancer proliferation and tumorigenesis.

Authors:  Wenjing Shen; Min Song; Jie Liu; Guangrong Qiu; Tianren Li; Yanjie Hu; Hongbo Liu
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.